CJC-1295 with DAC - Enhanced Pharma - 5mg × 2 vials
Buy CJC-1295 with DAC 5mg in India — Enhanced Pharma Research Grade
CJC-1295 with DAC - Weekly GHRH Analogue
→ View CJC-1295 with DAC buying guide for IndiaLong-acting GHRH analogue with Drug Affinity Complex extending half-life to 6–8 days. Provides continuous GH/IGF-1 elevation rather than pulsatile release. 1–2× weekly dosing.
Order this product
Factory-sealed box: 5mg × 2 vials. Ready for immediate dispatch.
🚚 Pan-India delivery / Cash on Delivery available
Why researchers reach for CJC-1295 with DAC
Weekly dosing convenience
DAC technology extends half-life to 6–8 days - practical 1–2× weekly research protocol vs. multiple daily injections of short-acting GHRH analogues.
Sustained GH/IGF-1 elevation
Continuous receptor stimulation produces sustained GH and IGF-1 elevation - a different pharmacological profile from pulsatile GHRP/GHRH dosing.
Body composition shifts
Studied for body-composition changes (lean mass, visceral fat) over 8–12 week cycles in published GH-axis research.
GHRP synergy potential
When stacked with a GHRP, the GHRH receptor and ghrelin receptor activate together - though synergy is somewhat blunted by CJC-DAC's sustained (vs. pulsatile) profile.
Community Insights
Self-reported by pep-pedia.org users and published research summaries. Not clinical evidence.
How CJC-1295 with DAC Works
DAC albumin binding
The DAC moiety covalently binds plasma albumin, shielding the peptide from rapid clearance and extending the half-life from minutes to days.
Continuous GHRH receptor activation
Sustained pituitary GHRH receptor stimulation produces ongoing GH release rather than the natural pulsatile rhythm.
IGF-1 elevation cascade
Sustained GH drives sustained hepatic IGF-1 production - the downstream effector behind most clinical GH-axis outcomes.
Mechanism based on peer-reviewed research. Read the full CJC-1295 with DAC research guide →
Stack It With
Full Specifications
Frequently Asked Questions
CJC-1295 with DAC vs without DAC?
Without DAC (Mod GRF 1-29), CJC-1295 has a ~30-minute half-life and produces pulsatile GH release similar to natural rhythms. With DAC, half-life extends to 6–8 days - sustained GH elevation but loss of pulsatility. Different research targets call for different versions.
How is the weekly dose split?
Pep-pedia documents 1–2 mg per week, split into 1–2 doses. Once-weekly dosing is convenient; twice-weekly (e.g. Mon/Thu) provides slightly more stable plasma levels. Either is well within the DAC-extended pharmacokinetic profile.
Will it suppress natural GH production?
Sustained GHRH-receptor stimulation can blunt natural pulsatile GH release over time - the trade-off for DAC's convenience. Cycle limits (8–12 weeks per pep-pedia) and stack design help mitigate this.
Reconstitution and storage?
Reconstitute lyophilized CJC-1295 with bacteriostatic water (BAC water - included). Refrigerate reconstituted vials at 2–8°C; stable for typical research timeframes given the long peptide half-life.
How does it compare to Tesamorelin?
Tesamorelin is an FDA-approved GHRH analogue for HIV-associated visceral lipodystrophy. CJC-1295 with DAC is a research peptide with longer half-life via DAC technology. Tesamorelin has the more rigorous human safety dataset; CJC-1295 with DAC offers easier dosing in research models.
Ready to order
CJC-1295 with DAC - Enhanced Pharma
₹9,300 · 5mg × 2 vials · Lyophilized powder + BAC water · Pan-India delivery
Add to CartResearch Use Only
This product is intended solely for laboratory and research purposes. It is not intended for human consumption, therapeutic use, or as a food or drug product. By purchasing, you confirm that this product will be used exclusively for legitimate research applications.